NASDAQ:OCX OncoCyte (OCX) Stock Price, News & Analysis $3.44 +0.05 (+1.47%) Closing price 04:00 PM EasternExtended Trading$3.44 +0.00 (+0.12%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About OncoCyte Stock (NASDAQ:OCX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OncoCyte alerts:Sign Up Key Stats Today's Range$3.26▼$3.5050-Day Range$2.52▼$4.1752-Week Range$1.92▼$4.75Volume88,149 shsAverage Volume56,295 shsMarket Capitalization$98.38 millionP/E RatioN/ADividend YieldN/APrice Target$4.42Consensus RatingModerate Buy Company OverviewOncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Read More… OncoCyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreOCX MarketRank™: OncoCyte scored higher than 45% of companies evaluated by MarketBeat, and ranked 587th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingOncoCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOncoCyte has only been the subject of 3 research reports in the past 90 days.Read more about OncoCyte's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OncoCyte are expected to grow in the coming year, from ($2.57) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OncoCyte is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OncoCyte is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncoCyte has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about OncoCyte's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.82% of the float of OncoCyte has been sold short.Short Interest Ratio / Days to CoverOncoCyte has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in OncoCyte has recently decreased by 2.33%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOncoCyte does not currently pay a dividend.Dividend GrowthOncoCyte does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.82% of the float of OncoCyte has been sold short.Short Interest Ratio / Days to CoverOncoCyte has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in OncoCyte has recently decreased by 2.33%, indicating that investor sentiment is improving. News and Social Media1.4 / 5News SentimentN/A News SentimentOncoCyte has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.Search InterestOnly 4 people have searched for OCX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added OncoCyte to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, OncoCyte insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,418,718.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.58% of the stock of OncoCyte is held by insiders.Percentage Held by Institutions55.35% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OncoCyte's insider trading history. Receive OCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address OCX Stock News HeadlinesOncocyte to Participate in 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comOncoCyte files to sell 10.61M shares of common stock for holdersApril 1, 2025 | markets.businessinsider.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. April 25, 2025 | Golden Portfolio (Ad)OncoCyte initiated with a Buy at Lake StreetMarch 29, 2025 | markets.businessinsider.comLake Street Initiates Coverage of OncoCyte (OCX) with Buy RecommendationMarch 29, 2025 | msn.comEarnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advancesMarch 26, 2025 | uk.investing.comOncocyte Corp. Reports Q4 2024 Results with $1.5 Million in Revenue and Significant Clinical Advancements in Transplant TestingMarch 26, 2025 | nasdaq.comOncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call TranscriptMarch 25, 2025 | msn.comSee More Headlines OCX Stock Analysis - Frequently Asked Questions How have OCX shares performed this year? OncoCyte's stock was trading at $2.38 at the beginning of 2025. Since then, OCX shares have increased by 43.3% and is now trading at $3.41. View the best growth stocks for 2025 here. How were OncoCyte's earnings last quarter? OncoCyte Co. (NASDAQ:OCX) announced its quarterly earnings data on Monday, March, 24th. The company reported $0.48 EPS for the quarter, topping the consensus estimate of ($0.40) by $0.88. The business earned $1.49 million during the quarter, compared to analysts' expectations of $0.16 million. OncoCyte had a negative net margin of 6,122.29% and a negative trailing twelve-month return on equity of 269.32%. Read the conference call transcript. When did OncoCyte's stock split? OncoCyte's stock reverse split before market open on Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are OncoCyte's major shareholders? Top institutional investors of OncoCyte include FNY Investment Advisers LLC (0.14%). Insiders that own company stock include Broadwood Partners, LP, Pura Vida Investments, Llc, Andrea S James, Andrew Arno, Alfred D Kingsley, Ronald Asbury Andrews, Andrew J Last, Josh Riggs and Li Yu. View institutional ownership trends. How do I buy shares of OncoCyte? Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of OncoCyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that OncoCyte investors own include Alibaba Group (BABA), Meta Platforms (META), Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY) and Ford Motor (F). Company Calendar Last Earnings3/24/2025Today4/25/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OCX CIK1642380 Weboncocyte.com Phone(949) 409-7600Fax510-521-3389Employees120Year FoundedN/APrice Target and Rating Average Stock Price Target$4.42 High Stock Price Target$5.00 Low Stock Price Target$4.00 Potential Upside/Downside+29.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($4.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,780,000.00 Net Margins-6,122.29% Pretax Margin-6,085.19% Return on Equity-269.32% Return on Assets-59.71% Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.50 Sales & Book Value Annual Sales$1.88 million Price / Sales51.69 Cash FlowN/A Price / Cash FlowN/A Book Value$2.48 per share Price / Book1.37Miscellaneous Outstanding Shares28,599,000Free Float17,177,000Market Cap$97.24 million OptionableNo Data Beta0.97 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:OCX) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.